Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where ...

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $200 from $223 and keeps a Neutral rating on the shares. The firm updated estimates ...

Additionally, AbbVie developed new immunology drugs in Skyrizi and Rinvoq.These moves are paying off. Skyrizi and Rinvoq were two of AbbVie's top three sellers in 2024. AbbVie's revenue dropped ...

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...